ET
NBIX icon

Entropy Technologies’s Neurocrine Biosciences NBIX Stock Holding History

Entropy Technologies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Sell
16,909
-6,768
-29% -$1M 0.11% 258
2026
Q1 		$3.12M Buy
23,677
+1,154
+5% +$153K 0.14% 194
2025
Q4 		$3.19M Buy
+22,523
New +$3.26M 0.17% 165

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Entropy Technologies's NBIX Position: Q2 2026 in Review

Entropy Technologies reduced its Neurocrine Biosciences (NBIX) stake by 29% in Q2 2026, selling an estimated $1M and leaving 16,909 shares worth $2.85M. The position accounts for 0.11% of the portfolio, ranked #258.

Entropy Technologies first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.19M in Q4 2025. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Entropy Technologies held 16,909 shares of Neurocrine Biosciences worth $2.85M as of Q2 2026.
  • Entropy Technologies sold 6,768 Neurocrine Biosciences shares in Q2 2026, an estimated $1M.
  • Neurocrine Biosciences made up 0.11% of Entropy Technologies's portfolio in Q2 2026, its #258 holding.
  • Entropy Technologies first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Entropy Technologies's Neurocrine Biosciences position peaked at $3.19M in Q4 2025.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.